artesunic acid has been researched along with Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Berköz, M; Keskin, S; Korkmaz, D; Krośniak, M; Özkan-Yılmaz, F; Özlüer-Hunt, A; Türkmen, Ö | 1 |
| Pan, J; Zheng, L | 1 |
| Baur, A; Berger, TG; Dieckmann, D; Efferth, T; Funk, JO; Schuler, G; Schultz, ES | 1 |
3 other study(ies) available for artesunic acid and Melanoma
| Article | Year |
|---|---|
Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Artesunate; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Progression; Humans; Melanoma; Signal Transduction; Skin Neoplasms; STAT3 Transcription Factor; Time Factors | 2021 |
The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells.
Topics: Adult; Analysis of Variance; Antimalarials; Antineoplastic Agents; Apoptosis; Artesunate; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Humans; Melanoma; Neoplasm Invasiveness; Phosphorylation; Signal Transduction; Uveal Neoplasms; Vincristine; Wnt Signaling Pathway | 2018 |
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisia; Artemisinins; Artesunate; Dacarbazine; Fatal Outcome; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Sesquiterpenes; Time Factors; Treatment Outcome; Uveal Neoplasms | 2005 |